A Randomized STudy of Ruxolitinib in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chonic Myeloid Leukemia; Patients with Molecular Evidence of Disease (S1712)
A Randomized STudy of Ruxolitinib in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chonic Myeloid Leukemia; Patients with Molecular Evidence of Disease (S1712)
Trial Category:
Hematologic
Phase
II
Contact(s)
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE
